↓ Skip to main content

Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, March 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study
Published in
Journal of Experimental & Clinical Cancer Research, March 2016
DOI 10.1186/s13046-016-0324-0
Pubmed ID
Authors

Iole Cordone, Francesco Marchesi, Serena Masi, Valentina Summa, Francesco Pisani, Roberta Merola, Giovanni Cigliana, Giulia Orlandi, Svitlana Gumenyuk, Francesca Palombi, Atelda Romano, Antonio Spadea, Daniela Renzi, Elena Papa, Marco Canfora, Laura Conti, Maria Concetta Petti, Andrea Mengarelli

Abstract

The achievement of complete response (CR) significantly correlates with a better clinical outcome in multiple myeloma (MM) patients treated with autologous stem cell transplant (ASCT). The depth of response is one of the most relevant factors to predict patient's outcome, however the definition of CR through standard criteria has shown several limitations. In this study we evaluated the minimal residual disease (MRD) in 50 consecutive MM patients who underwent an up-front tandem ASCT in our center, using a single-tube six-colors flow cytometry assay (FC) based on intra-cytoplasmic immunoglobulin (cy-Ig) light chains ratio evaluated on patient-specific plasma cells (PC) immune profile, in a real-life setting. With a sensitivity up to 10(-5), clonal-PC were documented by FC in 36.4 % (12/33) of patients in conventional CR after second transplant. The number of flow MRD-negative patients significantly increased after induction and first ASCT, but not between first and second transplant. The 5-years progression-free survival (5ys-PFS) of flow MRD-negative patients after second transplant was significantly better than patients who remained MRD-positive considering both all patients (5ys-PFS: 70 % vs 5 %) and patients in CR according to standard criteria (5ys-PFS: 67 % vs 0 %). FC remission through cy-Ig light ratio on PC sub-populations is a sensitive, highly informative, low-cost and routinely applicable MRD assay, a powerful tool in treatment response evaluation and a crucial marker of outcome in MM.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 24%
Other 3 18%
Student > Ph. D. Student 2 12%
Student > Bachelor 2 12%
Student > Master 2 12%
Other 1 6%
Unknown 3 18%
Readers by discipline Count As %
Medicine and Dentistry 8 47%
Biochemistry, Genetics and Molecular Biology 3 18%
Agricultural and Biological Sciences 1 6%
Immunology and Microbiology 1 6%
Engineering 1 6%
Other 0 0%
Unknown 3 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2016.
All research outputs
#3,380,867
of 7,430,207 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#96
of 391 outputs
Outputs of similar age
#127,294
of 278,241 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#5
of 24 outputs
Altmetric has tracked 7,430,207 research outputs across all sources so far. This one has received more attention than most of these and is in the 52nd percentile.
So far Altmetric has tracked 391 research outputs from this source. They receive a mean Attention Score of 1.5. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,241 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.